Last Updated

13 Mar 2019

Artemether-lumefantrine vs Chloroquine in patients with acute uncomplicated P. knowlesi malaria: a randomized open label trial in Sabah, Malaysia (CAN KNOW Trial)

Objectives

The investigators aim to test whether the fixed combination of artemether-lumefantrine is superior to chloroquine in order to define the optimal treatment for uncomplicated P. knowlesi infection in both adults and children in this region.

Principal Investigator
Rationale and Abstract

Preliminary studies have supported the background efficacy of local standard anti-malarial medications in the treatment of uncomplicated knowlesi malaria, however, there are no current WHO treatment guidelines for this infection.

There are both health cost benefits to a more rapidly acting agent, and due to difficulties with microscopic identification, there may be more effective treatments for all malaria species if an aligned treatment guideline could be supported.

Artemether-lumefantrine should also be compared against chloroquine due to the fact it is also a first line anti-malarial recommended in Malaysia, and there are potential differences in efficacy due to the different administration, absorption and half-life of artemether-lumefantrine.

ClinicalTrials.gov Identifier: NCT02001012

Study Design
Study Type  : Interventional  (Clinical Trial)
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Thematic Categories

Date

2014 Jan - 2015 Mar

Funding Details

Program grant 1037304; project grant 1045156
Project Site

Deep Dives